Related Experiment Videos
Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma
L M Rainwater1, W R Morgan, G G Klee
1Department of Urology, Mayo Clinic, Rochester, MN 55905.
Mayo Clinic Proceedings
|August 1, 1990
Summary
Prostate-specific antigen (PSA) aids in detecting prostate cancer and monitoring treatment. Elevated PSA levels can indicate advanced cancer or benign prostatic conditions, guiding further patient assessment.
Area of Science:
- Urology
- Oncology
- Biochemistry
Background:
- Prostate-specific antigen (PSA) isolation and radioimmunoassay development are key advancements.
- Available assays include both monoclonal and polyclonal methods for PSA detection.
Purpose of the Study:
- To evaluate PSA as a biomarker for prostate adenocarcinoma.
- To correlate PSA levels with pathologic tumor stage and treatment response.
Main Methods:
- Isolation and purification of PSA.
- Development of radioimmunoassay (RIA) for PSA.
- Correlation analysis of PSA levels with tumor stage and treatment outcomes.
Main Results:
- Higher pathologic tumor stages (C1-D2) correlate with elevated PSA levels.
- Increased PSA levels are also observed in benign prostatic diseases like hypertrophy and prostatitis.
- PSA is an effective marker post-radical prostatectomy and for monitoring radiation therapy.
Conclusions:
- Persistently elevated PSA post-surgery warrants assessment for residual or recurrent disease.
- Routine mass screening for prostate cancer using PSA is not currently cost-effective.